Pharma industry bangs the drum for HTA reform in Australia

20 May 2022
australia_big-1

The leading Australian trade body for the pharmaceutical industry, Medicines Australia, said it has alerted “hundreds of key stakeholders to get ready to engage” in the next government review of the country’s health technology assessment (HTA) system.

The review session is set to kick off in July, and will come just a couple of months after the country goes to the polls in a general election.

Medicines Australia said it was looking to “set the scene for major health reform” by the next government, with the issuing of hundreds of letters explaining the significance of the review.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical